ADC Therapeutics Announces Abstracts to be Presented at the 63 rd ASH Annual Meeting Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and

Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

Several presentations

will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and in combination

for the treatment of non-Hodgkin lymphomas

Lausanne, Switzerland,

November 4, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those

affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and

solid tumors, today announced abstracts for ZYNLONTA and ADCT-602 have been accepted for presentations at the 63rd American

Society of Hematology (ASH) Annual Meeting, which will be held virtually and in Atlanta, Georgia from December 11-14, 2021.

to sharing data on our targeted ADCs as single agents and in innovative combinations at the 2021 ASH Annual Meeting," said Joseph

Camardo, MD, Chief Medical Officer of ADC Therapeutics. "This will include presentations from investigators on subset data

from our pivotal Phase 2 study and data on the use of ZYNLONTA post-CAR-T. We are also encouraged by the anti-tumor activity and manageable

safety profile of ZYNLONTA in combination with ibrutinib. The Phase 2 protocol has recently been amended with a higher and more frequent

dose of ZYNLONTA to potentially enhance the response and to investigate this combination in earlier lines of therapy."

Details of ADC Therapeutics'

oral presentation are as follows:

Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)

Date and Time: Saturday,

December 11, 2021, 10:45 a.m. EST

Session: 627. Aggressive

Lymphomas: Clinical and Epidemiological: Population data for Aggressive NHL Management

Details of ADC Therapeutics'

poster presentations are as follows*:

Clinical Characteristics

and Responses of Patients with Relapsed or Refractory High-Grade B-cell Lymphoma Treated with Loncastuximab Tesirine in the LOTIS-2 Clinical

Date: Monday, December

Session: 626. Aggressive

Lymphomas: Prospective Therapeutic Trials: Poster III

Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma

Date: Sunday, December

Session: 605. Molecular

Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II

DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP inhibitors

Session: 622. Lymphomas:

Translational-Non-Genetic: Poster I

Details of an independently

developed ZYNLONTA poster are as follows:

Antibody-Drug Conjugate Loncastuximab Tesirine Achieved Responses in Patients with Diffuse Large B-cell Lymphoma Who Relapsed After Anti-CD19

Date: Sunday, December

Session: 626. Aggressive

Lymphomas: Prospective Therapeutic Trials: Poster II

Details of an independently

developed ADCT-602 poster are as follows:

of ADCT-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute

Lymphoblastic Leukemia

Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I

*Posters will be available in the poster

exhibit hall in the Georgia World Congress Center on these dates: December 11: 9:00 a.m.-7:30 p.m. EST; December 12 & 13: 9:00

Presenters planning to attend in-person are expected to present during the final two hours of the noted viewing time.

are available through the ASH online meeting program and will be published in the November supplemental issue of Blood.

(loncastuximab tesirine-lpyl)

ZYNLONTA is a CD19-directed antibody

drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine

(PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms.

This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration

(FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large

B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified

(NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated

patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line

therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant

and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on

overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit

in a confirmatory trial.

ZYNLONTA is also being evaluated as a

therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

About ADC Therapeutics

(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted

antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm

for patients with hematologic malignancies and solid tumors.

CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse

large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents.

Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase

1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing

clinical and preclinical development.

is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,

please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark

of ADC Therapeutics SA.

Tel.: +44 7879 627205

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 914-552-4625